LONDON (Alliance News) - Motif Bio PLC, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, said Friday it has appointed Andrew Powell as non-executive director, effective immediately.
Powell has served as general counsel at several biotechnology firms, including CollaGenex Pharmaceuticals, Imclone Systems, Cornerstone Therapeutics, Intermune and, most recently, Medivation.
"His extensive experience in the life sciences industry and strong expertise in commercialisation strategy, corporate expansion, governance, and mergers and acquisitions will provide Motif Bio's board of directors with important skills as the company moves forward," the company said.
Shares in Motif Bio were trading 15% higher at 9.72 pence each on Friday.
